Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Triamcinolone Acetonide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 5/20 | 0.84 |
| ▸ | LMNA | P02545 | 7/20 | 0.84 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.84 |
| ▸ | PGR | P06401 | 5/20 | 0.84 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.84 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | AR | P10275 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | USP2 | O75604 | 2/20 | 0.61 |
| ▸ | CNR1 | P21554 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triamcinolone Acetonide SCHEMBL10944236 | 0.99 | LMNA (0.83) | LMNAHIF1ACYP3A4NR3C1PGR | |
| Triamcinolone Acetonide SCHEMBL12323208 | 0.92 | HIF1A (1.00) | LMNAHIF1ACYP3A4NR3C1PGR | |
| Triamcinolone Acetonide SCHEMBL1639690 | 0.92 | HIF1A (1.00) | LMNAHIF1ACYP3A4NR3C1PGR | |
| Triamcinolone Acetonide SCHEMBL1692059 | 0.92 | HIF1A (1.00) | LMNAHIF1ACYP3A4NR3C1PGR | |
| Triamcinolone Acetonide SCHEMBL13839748 | 0.92 | HIF1A (1.00) | LMNAHIF1ACYP3A4NR3C1PGR | |
| Triamcinolone Acetonide SCHEMBL11911289 | 0.92 | HIF1A (1.00) | LMNAHIF1ACYP3A4NR3C1PGR | |
| Triamcinolone Acetonide SCHEMBL4448 | 0.92 | HIF1A (1.00) | LMNAHIF1ACYP3A4NR3C1PGR | |
| Triamcinolone Acetonide SCHEMBL16393966 | 0.92 | HIF1A (1.00) | LMNAHIF1ACYP3A4NR3C1PGR | |
| Triamcinolone Acetonide SCHEMBL21051778 | 0.92 | HIF1A (1.00) | LMNAHIF1ACYP3A4NR3C1PGR | |
| Triamcinolone Acetonide SCHEMBL4002585 | 0.92 | HIF1A (1.00) | LMNAHIF1ACYP3A4NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588181-B1 | CATHETER ASSEMBLY | SURMODICS INC (US) | 2021-11-24 | — | — | EP | disclosed |
| US-10596355-B2 | Catheter assembly | SURMODICS, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| EP-2588157-B1 | LIPID COATING FOR MEDICAL DEVICES DELIVERING BIOACTIVE AGENT | SURMODICS INC (US) | 2020-03-18 | — | — | EP | disclosed |
| US-8961457-B2 | Catheter assembly with guard | SURMODICS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8927000-B2 | Lipid coating for medical devices delivering bioactive agent | SURMODICS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8802121-B2 | Silane-functionalized hydrophobic α(1→4)glucopyranose polymers and polymeric matrices for implantation or injection | SURMODICS, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| EP-2588157-A1 | LIPID COATING FOR MEDICAL DEVICES DELIVERING BIOACTIVE AGENT | SurModics, Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| EP-2588181-A1 | CATHETER ASSEMBLY | SurModics, Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| EP-2544658-A2 | INJECTABLE DRUG DELIVERY SYSTEM | SurModics, Inc. (US) | 2013-01-16 | — | — | EP | disclosed |
| US-20120165786-A1 | LIPID COATING FOR MEDICAL DEVICES DELIVERING BIOACTIVE AGENT | BANK OF MONTREAL, AS COLLATERAL AGENT | 2012-06-28 | — | — | US | disclosed |
| WO-2008073295-A2 | LATENT STABILIZATION OF BIOACTIVE AGENTS RELEASABLE FROM IMPLANTABLE MEDICAL ARTICLES | SURMODICS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| EP-1926505-A1 | IN VIVO FORMED MATRICES INCLUDING NATURAL BIODEGRADABLE POLYSACCHARIDES AND OPHTHALMIC USES THEREOF | SurModics, Inc. (US) | 2008-06-04 | — | — | EP | disclosed |
| WO-2008060359-A2 | BIODEGRADABLE OCULAR IMPLANTS AND METHODS FOR TREATING OCULAR CONDITIONS | SURMODICS, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
| US-20080089923-A1 | Biodegradable ocular implants and methods for treating ocular conditions | SURMODICS MD, LLC | 2008-04-17 | — | — | US | disclosed |
| US-20070260054-A1 | Hydrophobic derivatives of natural biodegradable polysaccharides and uses thereof | SURMODICS, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070224247-A1 | Biodegradable hydrophobic polysaccharide-based drug delivery implants | SURMODICS MD, LLC | 2007-09-27 | — | — | US | disclosed |
| WO-2007109069-A2 | HYDROPHOBIC DERIVATIVES OF NATURAL BIODEGRADABLE POLYSACCHARIDES AND USES THEREOF | SURMODICS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20070218102-A1 | Biodegradable hydrophobic polysaccharide-based coatings | SURMODICS, INC. | 2007-09-20 | — | — | US | disclosed |
| WO-2007038126-A1 | IN VIVO FORMED MATRICES INCLUDING NATURAL BIODEGRADABLE POLYSACCHARIDES AND OPHTHALMIC USES THEREOF | SURMODICS, INC. (US) | 2007-04-05 | — | — | WO | disclosed |
| US-20070071792-A1 | In VIVO formed matrices including natural biodegradale polysaccharides and ophthalmic uses thereof | SURMODICS MD, LLC | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080089923-A1 | Biodegradable ocular implants and methods for treating ocular conditions | BMP2, MMP1, FUCA1 | NR3C1 2854/4885LMNA 2710/4885HIF1A 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.